These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 12928596)

  • 1. Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes.
    Yeh GC; Tao PL; Ho HO; Lee YJ; Chen JY; Sheu MT
    J Biomed Sci; 2003; 10(5):552-64. PubMed ID: 12928596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of a physiologically based pharmacokinetic model for the evaluation of single-point plasma phenotyping method of CYP2D6.
    Chen R; Rostami-Hodjegan A; Wang H; Berk D; Shi J; Hu P
    Eur J Pharm Sci; 2016 Sep; 92():131-6. PubMed ID: 27412587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative methods for CYP2D6 phenotyping: comparison of dextromethorphan metabolic ratios from AUC, single point plasma, and urine.
    Chen R; Wang H; Shi J; Hu P
    Int J Clin Pharmacol Ther; 2016 May; 54(5):330-6. PubMed ID: 26902503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.
    Capon DA; Bochner F; Kerry N; Mikus G; Danz C; Somogyi AA
    Clin Pharmacol Ther; 1996 Sep; 60(3):295-307. PubMed ID: 8841152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and polymorphic oxidation of dextromethorphan in a Japanese population.
    Nagai N; Kawakubo T; Kaneko F; Ishii M; Shinohara R; Saito Y; Shimamura H; Ohnishi A; Ogata H
    Biopharm Drug Dispos; 1996 Jul; 17(5):421-33. PubMed ID: 8830977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination.
    Tennezé L; Verstuyft C; Becquemont L; Poirier JM; Wilkinson GR; Funck-Brentano C
    Clin Pharmacol Ther; 1999 Dec; 66(6):582-8. PubMed ID: 10613613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan.
    Abduljalil K; Frank D; Gaedigk A; Klaassen T; Tomalik-Scharte D; Jetter A; Jaehde U; Kirchheiner J; Fuhr U
    Clin Pharmacol Ther; 2010 Nov; 88(5):643-51. PubMed ID: 20881950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers.
    Pope LE; Khalil MH; Berg JE; Stiles M; Yakatan GJ; Sellers EM
    J Clin Pharmacol; 2004 Oct; 44(10):1132-42. PubMed ID: 15342614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
    Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
    Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity.
    Hu OY; Tang HS; Lane HY; Chang WH; Hu TM
    J Pharmacol Exp Ther; 1998 Jun; 285(3):955-60. PubMed ID: 9618394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice.
    Jurica J; Bartecek R; Zourkova A; Pindurova E; Sulcova A; Kasparek T; Zendulka O
    J Clin Pharm Ther; 2012 Aug; 37(4):486-90. PubMed ID: 22548589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma profile and pharmacokinetics of dextromethorphan after intravenous and oral administration in healthy dogs.
    Kukanich B; Papich MG
    J Vet Pharmacol Ther; 2004 Oct; 27(5):337-41. PubMed ID: 15500572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous determination of dextromethorphan, dextrorphan, and guaifenesin in human plasma using semi-automated liquid/liquid extraction and gradient liquid chromatography tandem mass spectrometry.
    Eichhold TH; McCauley-Myers DL; Khambe DA; Thompson GA; Hoke SH
    J Pharm Biomed Anal; 2007 Jan; 43(2):586-600. PubMed ID: 16930908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vivo indices of CYP2D6 activity: comparison of dextromethorphan metabolic ratios in 4-h urine and 3-h plasma.
    Chládek J; Zimová G; Beránek M; Martínková J
    Eur J Clin Pharmacol; 2000 Dec; 56(9-10):651-7. PubMed ID: 11214771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates.
    Labbé L; Sirois C; Pilote S; Arseneault M; Robitaille NM; Turgeon J; Hamelin BA
    Pharmacogenetics; 2000 Jul; 10(5):425-38. PubMed ID: 10898112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omission of the deconjugation step in urine analysis and the unaltered outcome of CYP2D6 phenotyping with dextromethorphan.
    Basci NE; Bozkurt A; Kayaalp SO; Sayal A; Isimer A
    Eur J Drug Metab Pharmacokinet; 1998; 23(1):1-5. PubMed ID: 9625265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic differences in dextromethorphan metabolism.
    Vetticaden SJ; Cabana BE; Prasad VK; Purich ED; Jonkman JH; de Zeeuw R; Ball L; Leeson LJ; Braun RL
    Pharm Res; 1989 Jan; 6(1):13-9. PubMed ID: 2717511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance.
    Borges S; Li L; Hamman MA; Jones DR; Hall SD; Gorski JC
    Drug Metab Dispos; 2005 Jul; 33(7):1052-5. PubMed ID: 15821042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability of dextromethorphan (as dextrorphan) from sustained release formulations in the presence of guaifenesin in human volunteers.
    Demirbas S; Reyderman L; Stavchansky S
    Biopharm Drug Dispos; 1998 Nov; 19(8):541-5. PubMed ID: 9840216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A urine metabolic ratio of dextromethorphan and 3-methoxymorphinan as a probe for CYP3A activity and prediction of cyclosporine clearance in healthy volunteers.
    Min DI; Ku YM; Vichiendilokkul A; Fleckenstein LL
    Pharmacotherapy; 1999 Jun; 19(6):753-9. PubMed ID: 10391422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.